Ann: Half Yearly Report, page-3

Damn - they locked it for copy-pasting this time... The below is typed!

Here's the key points (as of December 31st, 2015);

* Revenue up 37% to $6.6M
* Over 135 centres now using CardioCel globally to date - up from 90 centres in July 2015
* CardioCel European label expansion enables greater access to adult heart valve market
* Completed recruitment of the HSV-2 Phase II study

Admedus sales continued to grow strongly, with revenue up 37% for the half year to $6.6M and total income, which includes rebates and grants, reaching $8.8M. Admedus continues to maintain its inventories across its product lines, which are in line with the previous year. Sales for CardioCel for the six months were $2.3M, close to the total registered for the previous full year and up 130% from the corresponding period [EOY 2014].

The closing cash for the period was $19.1M, down from $24.0M in the corresponding prior year period [EOY 2014]. The Company also successfully completed a placement of its shares, which raised $6.8M, net of expenses.

As expected the operating loss rose 19.3% to $13.6M. This was due to a number of factors including a planned increase in Sales and Marketing to support the ongoing rollout of the CardioCel product range, maintenance of product inventory and continued pursuit of new country approvals for CardioCel. Investment in Research and Development (R&D) also increased as we continued to refine the manufacturing process for the ADAPT tissue, and progressed our immunotherapies programs in the clinic. R&D is a central part of our long-term strategy to generate sustainable returns from the platform technologies and develop products that have multiple revenue streams